Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (42,856)	$ (100,606)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	32	4
Change in fair value of preferred stock tranche rights liability and preferred stock warrant liability	0	81,157
Stock-based compensation expense	3,061	922
Amortization of premiums and accretion of discounts on marketable securities, net	487	155
Amortization of right-of-use asset	137	0
Other non-cash expense	0	109
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,700	(3,881)
Other assets	(137)	(14)
Accounts payable	552	557
Accrued clinical trial expenses	2,570	147
Operating lease liability	(137)	0
Accrued expenses and other current liabilities	(562)	3,489
Net cash used in operating activities	(35,153)	(17,961)
Cash flows from investing activities
Purchases of marketable securities	(41,514)	(104,080)
Proceeds from maturities and sales of marketable securities	80,860	0
Purchases of property and equipment	(161)	(40)
Net cash provided by (used in) investing activities	39,185	(104,120)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	3,792	168,556
Proceeds from exercise of stock options	115	15
Proceeds from issuance of Series B milestone shares, net of issuance costs	0	30,031
Proceeds from exercise of Series A-1 warrant	0	1,250
Proceeds from exercise of common stock warrants	0	614
Net cash provided by financing activities	3,907	200,466
Net change in cash and cash equivalents	7,939	78,385
Cash and cash equivalents at the beginning of the period	122,162	43,777
Cash and cash equivalents at the end of the period	130,101	122,162
Supplemental disclosure of cash flow information
Cash paid for income taxes	0	0
Cash paid for interest	0	0
Supplemental disclosure of noncash financing activities
Right-of-use assets obtained in exchange for operating lease liabilities	242	0
Conversion of convertible preferred stock into common stock upon IPO	0	174,504
Reclassification of preferred stock tranche rights liability upon share issuance	0	81,190
Reclassification of warrant liability upon exercise of preferred stock warrant	$ 0	$ 5,380